

Synthesis and antitubercular activity of new N,N-diaryl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamides

Amini M., Navidpour L., *Shafiee A.

Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences
Research Center, Tehran University of Medical Sciences, Tehran, 14174, Iran

Received 5 June 2007; Revised 23 Oct 2007; Accepted 15 Nov 2007

ABSTRACT

Background and the purpose of the study: Dihydropyridines having carboxamides in 3 and 5 positions show anti-tuberculosis activity. The purpose of the present study was to synthesize new DHPs having possible anti-tuberculosis activity.

Methods: 4,5-Dichloroimidazole-2-carboxaldehyde was condensed with N-arylacetoacetamides and ammonium acetate in methanol to give N,N-diaryl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamides. All compounds were screened for their antitubercular activity against *Mycobacterium tuberculosis* (H₃₇Rv).

Results and major conclusion: Some of the new synthesized compounds exhibited a moderate activity in comparison to rifampicin.

Keywords: Antituberculosis, Dihydropyridine, Dichloroimidazole

INTRODUCTION

The dihydropyridines (DHPs) are well-known drugs for the treatment of hypertension and cardiovascular disorders (1). They also have antiallergic (2), anti-inflammatory (3) and Ca²⁺ channel antagonist activities (4). Recently, the syntheses of DHPs with respect to Multidrug Resistance (MDR) reversal in tumor cell gave a new dimension to their applications (5-6). In addition, 1,4-DHP class of compounds are excellent starting synthons for development of antitubercular agents (7-9). It has been demonstrated that substitution of aryl-amide group for dicarboxylic esters moiety reduces the Ca²⁺ channel blocker activity and increases antitubercular activity (10).

Previous studies have shown a moderate to good antitubercular activity for several aryl six-membered ring at 4-position and aryl-amide side chain in C₃ and C₅ of DHPs against *Mycobacterium tuberculosis* (H₃₇Rv) (7-9).

As a part of our ongoing research to design novel dihydropyridines (11-17), in this study the design, synthesis and antitubercular activity of N,N-diaryl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine-dicarboxamides **3a-j** are described.

MATERIAL AND METHODS


Chemistry

Melting points were determined using a Kofler hot stage apparatus and are uncorrected. ¹HNMR spectra were run on a Bruker FT-80 spectrometer. TMS was used as an internal standard. Mass spectra were measured with a Finnigan TSQ-70 spectrometer at 70 eV. The IR spectra were recorded on a Nicolet FTIR 550 spectrophotometer.

The compounds **3a-j** (Table 1) were synthesized according to Scheme 1, from condensation of 4,5-dichloroimidazole-2-carboxaldehyde **1**, N-arylacetoacetamide **2** and ammonium acetate in methanol. 4,5-Dichloroimidazole-2-carboxaldehyde was prepared according to reported method (13). N-Arylacetoacetamides (**2a-j**) were synthesized according to modified Clemens method (18) by simple condensation of 2,2,6-trimethyl-1,3-dioxin-4-one with the appropriate arylamine.

General procedure for the preparation of compounds **3a-j**.

To 3 mmoles of 4,5-dichloroimidazole-2-carboxaldehyde **1** was added 6 mmoles of N-arylacetoacetamide **2** and 20 mmoles of ammonium acetate in 20 ml of methanol. The mixture was refluxed for 24 h and the solvent was



R= (a) H, (b) 3-F, (c) 4-F, (d) 3-Cl, (e) 4-Cl,

(f) 3,4-Cl₂, (g) 3-Br, (h) 4-Br, (i) 3-nitro, (j) 4-nitro.

Scheme 1

removed under reduced pressure. The residue was purified by column chromatography using chloroform/methanol (20:1) as eluent. Crystallization from chloroform & petroleum ether gave pure compounds **3a-j**.

N,N-Diphenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3a**).

IR (KBr) ν cm⁻¹: 3277 (NH), 1670 (C=O). ¹HNMR (DMSO-d₆) δ : 2.17 (s, 6H, Me_{2,6}), 4.80 (s, 1H, H₄), 6.99-7.80 (m, 10H, aromatic), 8.6 (bs, 1H, NH-dihydropyridine), 9.90 (bs, 2H, NH-amide), 12.8 (bs, 1H, NH-imidazole). MS: m/z (%) 391 (M⁺, 4), 388 (38), 345 (36), 296 (76), 253 (90), 196 (20), 136 (19), 106 (36), 93 (100).

N,N-Di-3-fluorophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3b**).

IR (KBr) ν cm⁻¹: 3258 (NH), 1673 (C=O). ¹HNMR (DMSO-d₆) δ : 2.15 (s, 6H, Me_{2,6}), 4.95 (s, 1H, H₄), 6.81-7.15 (m, 2H), 7.38-7.55 (m, 6H), 8.65 (bs, 1H, NH-dihydropyridine), 9.90 (bs, 2H, NH-amide), 12.55 (bs, 1H, NH-imidazole). MS: m/z (%) 518 (M⁺, 3), 381 (48), 296 (45), 271 (100), 160 (10), 137 (83), 111(80), 82 (42).

N,N-Di-4-fluorophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3c**).

IR (KBR) ν cm⁻¹: 3245 (NH), 1665 (C=O). ¹HNMR (DMSO-d₆) δ : 2.15 (s, 6H, Me_{2,6}), 4.98 (s, 1H, H₄), 7.0-7.32 (m, 4H), 6.55-7.65 (m, 4H), 8.60 (bs, 1H, NH-dihydropyridine), 9.95 (bs, 2H, NH-amide), 12.5 (bs, 1H, NH-imidazole). MS: m/z (%) 518 (M⁺, 2), 406 (17), 381 (40), 353 (19), 296 (42), 271 (100), 233 (10), 160(15), 137 (83), 111 (88), 109 (78), 82 (38).

N,N-Di-3-chlorophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3d**).

IR (KBr) ν cm⁻¹: 3266 (NH), 1670 (C=O). ¹HNMR (DMSO-d₆) δ : 2.15 (s, 6H, Me_{2,6}), 4.90 (s, 1H, H₄), 6.91-7.15 (m, 6H), 7.65-7.75 (m, 2H), 8.65 (bs, 1H, NH-dihydropyridine), 9.90 (bs, 2H, NH-amide), 12.55 (bs, 1H, NH-imidazole). MS: m/z (%) 518 (M⁺, 4), 406 (20), 381 (40), 353 (10), 296 (40), 271 (100), 233 (10), 137 (80), 111 (90), 109 (85), 82 (38).

N,N-Di-4-chlorophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3e**).


IR (KBr) ν cm⁻¹: 3244 (NH), 1675 (C=O). ¹HNMR (DMSO-d₆) δ : 2.15 (s, 6H, Me_{2,6}), 4.95 (s, 1H, H₄), 7.33 (d, J = 8Hz, 4H), 7.75 (d, J = 8Hz, 4H), 8.60 (bs, 1H, NH-dihydropyridine), 9.90 (bs, 2H, NH-amide), 12.40 (bs, 1H, NH-imidazole). MS: m/z (%) 518 (M⁺, 10), 406 (15), 381 (38), 296 (28), 271 (71), 137 (85), 111 (100), 109 (83), 83 (42).

N,N-Di-3,4-dichlorophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3f**).

IR (KBr) ν cm⁻¹: 3275 (NH), 1669 (C=O). ¹HNMR (DMSO-d₆) δ : 2.10 (s, 6H, Me_{2,6}), 4.92 (s, 1H, H₄), 7.36-7.51(m, 4H), 8.05 (s, 2H), 8.40 (bs, 1H, NH-dihydropyridine), 10.26 (bs, 2H, NH-amide), 12.40 (bs, 1H, NH-imidazole). MS: m/z (%) 577 (M⁺, 10), 549 (6), 368 (18), 255 (8), 236 (18), 138 (12), 123 (20), 111 (35), 97 (47), 83 (70), 57 (100).

N,N-Di-3-bromophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3g**).

IR (KBr) ν cm⁻¹: 3250 (NH), 1677 (C=O). ¹HNMR (DMSO-d₆) δ : 2.20 (s, 6H, Me_{2,6}), 4.90

Table 1. Physical data and antitubercular screening results of compounds **3a-j** against *M. Tuberculosis* (*H₃Rv* strain)

Comp. No.	R	Mp (°C)	Yield (%)	Inhibition (%)
3a	H	260-262	45	9
3b	3-F	159-161	30	0
3c	4-F	175-176	27	13
3d	3-Cl	170-172	52	50
3e	4-Cl	168-169	50	12
3f	3,4-Cl ₂	254-256	47	34
3g	3-Br	178-180	50	1
3h	4-Br	254-255	49	0
3i	3-NO ₂	250-253	48	43
3j	4-NO ₂	285-288	50	43
rifampicin				>98

(s, 1H, H₄), 6.90-7.25 (m, 4H), 7.45-7.65 (m, 2H), 8.05 (bs, 1H, NH-dihydropyridine), 9.90 (bs, 2H, NH-amide), 12.55 (bs, 1H, NH-imidazole). MS: m/z (%) 638 (M⁺, 2), 503 (8), 415 (5), 331 (100), 269 (23), 197 (42), 173 (30), 106 (29), 63 (18).

N,N-Di-4-bromophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3h**).

IR (KBr) ν cm⁻¹: 3244 (NH), 1675 (C=O). ¹HNMR (DMSO-d₆) δ : 2.20 (s, 6H, Me_{2,6}), 4.90 (s, 1H, H₄), 7.40 (d, J = 7.8 Hz, 4H), 7.60 (d, J = 7.8 Hz, 4H), 8.40 (bs, 1H, NH-dihydropyridine), 10.18 (bs, 2H, NH-amide), 12.40 (bs, 1H, NH-imidazole). MS: m/z (%) 638 (M⁺, 2), 577 (10), 331 (15), 242 (22), 142 (100), 100 (72), 44 (62).

N,N-Di-3-nitrophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3i**).

IR (KBr) ν cm⁻¹: 3245 (NH), 1675 (C=O). ¹HNMR (DMSO-d₆) δ : 2.18 (s, 6H, Me_{2,6}), 4.95 (s, 1H, H₄), 7.23-7.58 (m, 2H), 7.75-7.85 (m, 4H), 8.50-8.65 (m, 2H), 8.75 (bs, 1H, NH-dihydropyridine), 10.25 (bs, 2H, NH-amide), 12.80 (bs, 1H, NH-imidazole). MS: m/z (%) 572 (M⁺, 10), 551 (25), 381 (10), 368 (60), 236 (58), 98 (65), 83 (78), 43 (100).

N,N-Di-4-nitrophenyl-4-(4,5-dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamide (**3j**).

IR (KBr) ν cm⁻¹: 3254 (NH), 1670 (C=O). ¹HNMR (DMSO-d₆) δ : 2.15 (s, 6H, Me_{2,6}), 4.95

(s, 1H, H₄), 7.80 (d, J = 9Hz, 4H), 8.20 (d, J = 9Hz, 4H), 8.85 (bs, 1H, NH-dihydropyridine), 10.40 (bs, 2H, NH-amide), 12.80 (bs, 1H, NH-imidazole). MS: m/z (%) 572 (M⁺, 35), 551 (15), 523 (10), 368 (17), 313 (22), 264 (15), 236 (25), 111 (38), 83, (60), 57 (75), 45 (100).

RESULT AND DISCUSSION

All compounds were tested against *M. tuberculosis* H₃₇Rv strain at concentration of 6.25 μ g/ml in DMSO. Rifampicin was used as a reference drug. Primary screening was conducted in Bactec 12 B medium using the Bactec 460 radiometric system (19). The antitubercular activity and physical data of compounds **3a-j** are summarized in Table 1. From the Results it appears that substitution of 4,5-dichloroimidazole ring at 4-position of 1,4-DHP affects the antitubercular activity when 3,5-diester group in classic DHP structure was replaced by carboxamide moiety. The results demonstrate that a five member heterocyclic group with electron withdrawing substituent is a suitable bioisoster for nitro phenyl group which was previously reported as antitubercular agent (10).

Comparison of the activities of **3a-j** indicates that the most active compound is **3d** with 3-chlorophenyl group at 3,5 dicarbox-amide position. 3-Nitrophenyl and 4-nitrophenyl substituted compounds were also relatively active, but other substitutions did not show good activity. Compounds **3a-j** could serve as valuable probes to study the structure-function relationships for antitubercular activity.

ACKNOWLEDGMENT

The authors are very thankful to the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF), funded by the National Institute of Allergy and Infectious Diseases, a division of the National Institute of Health, USA,

for providing biological screening results. This work was supported by grants from the Research Council of Tehran University of Medical Sciences, INSF (Iran National Science Foundation) and Iran Chapter of TWAS.

REFERENCES

1. Mannhold R. Medicinal chemistry of DHP-like calcium antagonists. *Drugs of Today* 1994;30:103-122.
2. Cooper K, Johnathon FM. Dihydropyridine anti-allergic and anti-inflammatory agents. *Eur Patent* 294074 1988.
3. Johnson RC, Taylor DJ. 4-(Nitroaryl) dihydropyridines. *US Patent* 4758669 1998.
4. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. *Pharmacol Rev* 1986;38:321-325.
5. Tanabe H, Tasaka S, Ohmori H, Gomi N, Sasaki Y, Machida T, Iino M, Kiue A, Naito S, Kuwano M. Newly synthesized dihydropyridine derivatives as modulators of P-glycoprotein-mediated multidrug resistance. *Bioorg Med Chem* 1998;6:2219-2227.
6. Tasaka S, Ohmori H, Gomi N, Iino M, Machida T, Kiue A, Naito S, Kuwano M. Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance. *Bioorg Med Chem Lett* 2001;11:275-277.
7. Eharkar P S, Desai B, Gaveria H, Varu B, Loriya R, Naliapara Y, Shah A, Kulkarni VM. Three-dimensional quantitative structure-activity relationship of 1,4-dihydropyridines as antitubercular agents. *J Med Chem* 2002;45:4858-4867.
8. Desai B, Sureja D, Nalapara Y, Shah A, Saxena AK. Synthesis and QSAR studies of 4-substituted phenyl-2,6-dimethyl-3,5-bis-N-(substituted phenyl)carbamoyl-1,4-dihydropyridines as potential antitubercular agents. *Bioorg Med Chem* 2001;9:1993-1998.
9. Gaveriya H, Desai B, Vora V, Shah A. Synthesis and antitubercular activity studies of some unsymmetrical 1,4-dihydropyridines. *Indian J Pharm Sci* 2002;64:59-62.
10. Gevariya H, Desai B, Vora V, Shah A. Synthesis of some new unsymmetrical 1,4-dihydropyridine derivatives as potent antitubercular agents. *Heterocycl Commun* 2001;5:481-484.
11. Shafiee A, Miri R, Dehpour AR, Soleymani F. Synthesis and calcium-channel antagonist activity of nifedipine analogues containing nitroimidazolyl substituent in guinea-pig ileal smooth muscle. *Pharm Sci* 1996;2:541-543.
12. Pourmorad F, Hadizadeh F, Shafiee A. Synthesis and calcium-channel antagonist activity of 4-imidazolyl-1,4-dihydropyridines. *Pharm Sci* 1997;3:165-168.
13. Shafiee A, Dehpour AR, Hadizadeh F, Azimi M. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4(5)-chloro-2-methyl-5(4)-imidazolyl substituent. *Pharm Acta Helv* 1998;73:75-79.
14. Amini M, Golabchifar A, Dehpour AR, Pirali Hamedani M, Shafiee A. Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing dichloroimidazolyl substituents. *Arzneim-Forsch/Drug Res* 2002;52:21-26.
15. Davood A, Khodarahmi G, Alipour E, Dehpour A, Amini M, Shafiee A. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 4(5)-chloro-2-methyl-5(4)-imidazolyl substituent. *Boll Chim Farm* 2001;140:381-386.
16. Miri R, Niknahad H, Vazin A, Azarpira A, Shafiee A. Synthesis and smooth muscle calcium channel antagonist effects of new derivatives of 1,4-dihydropyridine containing nitroimidazolyl substituent. *DARU* 2002;10:130-135.
17. Ghodsi S, Alipour E, Amini M, Miri R, Tagi-Ganji KM, Hosseini M, Mirkhani H, Shafiee A. The synthesis and characterization of new asymmetrical dihydropyridine derivatives containing a 2,4-dichloro-5-thiazolyl substituent. *Phosphorus Sulfur and Silicon* 2006;181:2435-2444.
18. Clemens RJ, Hyatt JA. Acetoacetylation with 2,2,6-trimethyl-4H-1,3-dioxin-4-one: a convenient alternative to diketene. *J Org Chem* 1985;50:2431-2433.
19. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against *Mycobacterium tuberculosis* and *Mycobacterium avium*. *Antimicrob Agents Chemother* 1997;41:1004-1009.